### In vitro / physico-chemical Data <a id="invitro-and-physico-chemical-data"></a>

A literature search was performed to collect available information on physicochemical properties of levonogestrel. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value** | Source                                     | **Description**                                 |
| :-------------- | -------- | --------- | ------------------------------------------ | ----------------------------------------------- |
| MW| g/mol|312.44| [Bayer 2009](#main-references)| Molecular weight|   
| logP | |3.3-3.8| [Drugbank](#main-references), [Pubchem](#main-references)| Molecular weight|   |
| Solubility (pH) |     mg/l  |         14 (6.5)     | [Rao 2011](#main-references)| FaSSIF Solubility|
| Specific Protein binding: SHBG Koff           | 1/min        | 17.4       | [Li 1990](#main-references)                | sex-hormone binding globulin rate of protein-ligand dissociation                    |
| Specific Protein binding: SHBG Kd|    Î¼mol/L       | 0.0005                               |[Li 1990](#main-references)        |sex-hormone binding globulin dissociation constant|

### Clinical Data  <a id="clinical-data"></a>

A literature search was performed to collect available clinical data on levonogestrel in healthy adults.

#### Model Building <a id="model-building"></a>

The following studies were used for model building (training data):

| Publication                 |Dose | Route| Arm / Treatment / Information used for model building |
| :-------------------------- |---| -----|----------------------------------------------- |
| [Humpel 1978](#main-references) | 0.03 mg       |IV    |Healthy women receiving a QD administration of lenovogestrel 
| [Cicali 2021](#main-references) | 0.09 mg       |IV    |Healthy women receiving a single dose administration of lenovogestrel 
| [Back 1981](#main-references) | 0.15 mg       |IV    |Healthy women receiving a single dose administration of lenovogestrel 
| [Back 1981](#main-references) | 0.25 mg       |IV    |Healthy women receiving a single dose administration of lenovogestrel 
| [Back 1987](#main-references) | 0.25 mg       |IV    |Healthy women receiving a single dose administration of lenovogestrel 
| [Cicali 2021](#main-references) | 0.03 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Cicali 2021](#main-references) | 0.03 mg       |PO    |Healthy women receiving QD administration for 28 days of lenovogestrel 
| [Cicali 2021](#main-references) | 0.09 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Kuhnz 1994](#main-references) | 0.125 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Back 1981](#main-references) | 0.15 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Goebelsmann 1986](#main-references) | 0.15 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Humpel 1978](#main-references) | 0.15 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Menon 2016](#main-references) | 0.15 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel
| [Back 1981](#main-references) | 0.25 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Back 1987](#main-references) | 0.25 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Cicali 2021](#main-references) | 0.27 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Humpel 1978](#main-references) | 0.3 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel in the fed state | [Kives 2005](#main-references) | 0.5 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel  
| [NovoNordisk 2007](#main-references) | 0.15 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Kives 2005](#main-references) | 0.75 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel
| [Kook 2002](#main-references) | 0.75 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Tremblay 2001](#main-references) | 0.75 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Natavio 2019](#main-references) | 1.5 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Johansson 2002](#main-references) | 1.5 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Praditpan 2017](#main-references) | 1.5 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel 
| [Praditpan 2017](#main-references) | 1.5 mg       |PO    |Healthy women receiving a single dose administration of lenovogestrel in the fed state